Differential diagnosis between non-malignant hematological adverse events associated with PARPi and myeloid neoplasms post PARPi
| Transient myelosuppression | Myeloid neoplasms post PARPi | |
| Incidence | Most frequent PARPi-related adverse event | Rare |
| Timing | Typically within the first 3 months | Median onset: 7–24 months |
| PARPi suspension | Regression | Persistence (>4 weeks) |
| Grade | Mild-to-moderate (G1–G2) | Severe (G3–G4) |
PARPi, poly (ADP-ribose) polymerase inhibitor.